Leflunomide Aspire Pharma (Malta)

Leflunomide, the active ingredient in Leflunomide Aspire Pharma, is a dihydroorotate dehydrogenase inhibitor presented as a strength/form for oral use. It treats rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomide Aspire Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Leflunomide is a disease‑modifying antirheumatic drug that acts on immune‑mediated joint diseases.

Rheumatoid arthritis: reduces disease activity, slows joint damage and improves functional capacity. Psoriatic arthritis: alleviates joint inflammation and may improve associated skin lesions.

Leflunomide may cause a range of adverse reactions.

Common Side Effects: - Diarrhea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Alopecia: reversible hair thinning. - Rash: skin irritation or erythema. - Elevated liver enzymes: mild transaminase rise. - Hypertension: increase in blood pressure.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Bone marrow suppression: anemia, leukopenia, or thrombocytopenia. - Interstitial lung disease: pulmonary inflammation and fibrosis.

Before initiating therapy, clinicians should assess baseline health and monitor regularly.

Monitor liver function: obtain baseline and periodic ALT/AST tests. Assess blood pressure: check regularly during treatment. Screen for infections: evaluate for active infections before starting. Avoid in pregnancy: contraindicated due to teratogenic risk. Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture.

Leflunomide can interact with several medicines; careful review is required.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect, risk of bleeding. - Teriflunomide: additive toxicity, especially hepatic. - Live vaccines: heightened risk of infection. - Methotrexate: enhanced hepatotoxicity.

Moderate Interactions (Monitor Closely): - Statins: increased risk of myopathy. - Carbamazepine: reduces leflunomide plasma levels. - Oral contraceptives: may diminish contraceptive efficacy.